Teitur Trophics reported positive Phase I results for its therapeutic peptide TT-P34 in Parkinson’s disease, highlighting measurable central nervous system exposure and a favorable early safety profile. The company said the trial assessed whether the peptide reached fluid around the brain and spinal cord in the range it believes is needed to produce disease-relevant effects. TT-P34 is designed with a dual mechanism tied to mitochondrial and lysosomal dysfunction, delivered via a peptide derived from the SorCS2 receptor. Company commentary emphasized that TT-P34 is intended to reactivate CREB to restore mitochondrial and lysosomal functionality. Teitur also reported changes in lysosome-related protein markers in cerebrospinal fluid consistent with the hypothesized target engagement. The company plans a Phase II trial in 2027 to test whether TT-P34 can translate early pharmacodynamics and exposure into clinical benefit.